意大利新冠疫苗后急性阑尾炎的自对照病例系列研究
该研究采用自对照病例系列设计,基于意大利区域健康数据库链接,纳入2020年12月27日至2021年9月30日所有≥12岁疫苗接种者,评估mRNA疫苗和病毒载体新冠疫苗与急性阑尾炎的关联。结果显示总体人群未见风险增加,但性别亚组分析中男性首剂mRNA-1273后14-27天及女性单剂Ad26.COV2-S后风险升高,作者提示需谨慎解读。
要点
- 总体人群未观察到BNT162b2、mRNA-1273、ChAdOx1-S或Ad26.COV2-S与急性阑尾炎风险增加相关。
- 男性首剂mRNA-1273后14-27天阑尾炎风险升高(RI 1.71,95%CI 1.08-2.70,p=0.02)。
- 女性单剂Ad26.COV2-S后阑尾炎风险升高(RI 4.40,95%CI 1.29-15.01,p=0.02),需谨慎解读。
核心结论
- 在总体人群中,未发现BNT162b2、ChAdOx1-S、mRNA-1273和Ad26.COV2-S与急性阑尾炎存在关联的证据。
- 性别亚组分析结果需谨慎看待,不能排除多重比较问题,且缺乏生物学机制和相关文献支持。
研究设计与样本
- 采用自对照病例系列(SCCS)设计,评估新冠疫苗接种与急性阑尾炎发病的关联。
- 研究基于TheShinISS应用链接区域健康数据库,纳入2020年12月27日至2021年9月30日所有≥12岁疫苗接种者。
- 急性阑尾炎通过住院出院诊断或急诊就诊识别,排除既往5年内有阑尾炎诊断者。
- 暴露定义为BNT162b2、mRNA-1273、ChAdOx1-S的第一或第二剂及Ad26.COV2-S的单剂。
- 风险区间为接种后42天并分为预设亚期,参照期为风险区间外的观察时间,采用修改后SCCS方法估计相对发病率和95%置信区间。
主要发现
- 42天风险区间内共发生1285例急性阑尾炎事件,其中首剂后727例,第二剂后558例。
- 主要分析中,四种疫苗均未观察到急性阑尾炎风险增加。
- 男性首剂mRNA-1273后14-27天风险升高(RI 1.71;95%CI 1.08-2.70;p=0.02)。
- 女性单剂Ad26.COV2-S后14-27天风险升高(RI 4.40;95%CI 1.29-15.01;p=0.02)。
临床怎么用
- 临床应知总体人群中新冠疫苗接种未增加急性阑尾炎风险,无需因此改变接种决策。
- 对男性接种mRNA-1273后14-27天及女性接种Ad26.COV2-S后出现腹痛者,可保持警惕但不应过度解读。
局限性
- 性别亚组分析结果可能受多重比较影响,不能排除假阳性。
- 缺乏生物学机制证据及其他疫苗或同类疫苗的类似效应证据支持亚组结论。
- 研究仅基于意大利区域健康数据库,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Cases of appendicitis were identified in the pivotal randomized clinical trial on BNT162b2 mRNA vaccine and reported from coronavirus disease 2019 (COVID-19) vaccine pharmacovigilance systems. Three cohort studies and two self-controlled case series (SCCS) studies evaluating the association between mRNA vaccines and appendicitis reported discordant results. To address this uncertainty, the present study examines in a large population, with a SCCS design, the association between mRNA (BNT162b2 and mRNA-1273) and, for the first time, viral vector (ChAdOx1-S and Ad26.COV2-S) COVID-19 vaccines and acute appendicitis. METHODS: The SCCS study design was used to evaluate the association between COVID-19 vaccination and subsequent onset of acute appendicitis. The study was based on record linkage of health archives through TheShinISS application, a statistical tool that locally processes data from regional health care databases according to ad hoc, study-tailored and common data model. The study population included all vaccinated subjects ≥ 12 years old between 27 December 2020 and 30 September 2021. The acute appendicitis was identified through discharge diagnoses of hospital admissions or emergency department visits. Incident cases were defined as those who experienced a first event of acute appendicitis in the study period, excluding subjects with a diagnosis of appendicitis in the previous 5 years. Exposure was defined as the first or second dose of BNT162b2, mRNA-1273 and ChAdOx1-S and the single dose of Ad26.COV2-S. The risk interval was defined as 42 days from the first or second vaccination dose and divided into pre-specified risk subperiods; the reference period was the observation time outside the risk interval. Relative incidences (RI) and 95% confidence intervals (95% CI) were estimated with the SCCS method 'modified for event-dependent exposures', through unbiased estimating equations. The seasonal component was considered as a time-dependent covariate. RESULTS: In the 42-day risk interval 1285 incident cases of acute appendicitis occurred: 727 cases after the first dose and 558 cases after the second dose. In the main analysis, no increased risks of acute appendicitis were observed in subjects vaccinated with BNT162b, mRNA-1273, ChAdOx1-S and Ad26.COV2-S. The subgroup analyses by sex showed an increased risk in the 14-27 day risk interval, in males after the first dose of mRNA-1273 (RI of 1.71; 95% CI 1.08-2.70, p = 0.02) and in females after the single dose of Ad26.COV2-S (RI of 4.40; 95% CI 1.29-15.01, p = 0.02). CONCLUSIONS: There was no evidence of association of BNT162b, ChAdOx1-S, mRNA-1273 and Ad26.COV2-S with acute appendicitis in the general population. The results of the subgroup analyses by sex needs to be considered with caution. The multiplicity issue cannot be excluded being these hypotheses two of several hypotheses tested. In addition, relevant literature on the biological mechanism of the disease and evidence of similar effects with other vaccines or with the same vaccines are still lacking to provide strong support for a conclusion that there is an harmful effect in males and females with mRNA-1273 and Ad26.COV2-S.
引用
- Morciano C, Massari M, Cutillo M, et al. Acute Appendicitis After COVID-19 Vaccines in Italy: A Self-Controlled Case Series Study. Drug Saf. 2024. PMID: 39068268. doi:10.1007/s40264-024-01462-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。